UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: March 15, 2006
(Date of earliest event reported)
ORTHOLOGIC CORP.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
000-21214
|
|
86-0585310 |
|
|
|
|
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.) |
| |
|
|
| 1275 West Washington Street, Tempe, Arizona
|
|
85281 |
|
|
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code:
(602) 286-5520
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| |
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| |
| |
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
| |
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)) |
| |
| |
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Section 8 — Other Events
Item 8.01 Other Events.
On March 15, 2006, OrthoLogic Corp. issued a press release announcing the results of an
analysis of topline data from its Phase 3 clinical trial of the novel synthetic peptide
Chrysalin® (TP508) in unstable, displaced distal radius (wrist) fractures. Treatment
with 10µg Chrysalin did not demonstrate a statistically significant benefit compared to placebo in
the primary efficacy endpoint of time to removal of immobilization. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated by reference herein.